TWA
PTGX icon

TCI Wealth Advisors’s Protagonist Therapeutics PTGX Stock Holding History

TCI Wealth Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-129
Closed -$2.97K – 1725
2023
Q1 		$2.97K Buy
+129
New +$2.17K ﹤0.01% 1856
2022
Q4 		– Sell
-387
Closed -$3K – 2626
2022
Q3 		$3K Buy
+387
New +$3.66K ﹤0.01% 1821
2022
Q1 		– Sell
-219
Closed -$7K – 2402
2021
Q4 		$7K Buy
219
+73
+50% +$2.31K ﹤0.01% 1448
2021
Q3 		$3K Buy
146
+51
+54% +$2.17K ﹤0.01% 1992
2021
Q2 		$4K Buy
95
+32
+51% +$1.06K ﹤0.01% 1615
2021
Q1 		$2K Buy
+63
New +$1.59K ﹤0.01% 1855

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCI Wealth Advisors's PTGX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 129 shares — an estimated $2.97K sold.

TCI Wealth Advisors first reported a position in PTGX in Q1 2021 and held it in 6 quarters. The position peaked at $7K in Q4 2021. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 129 Protagonist Therapeutics shares in Q2 2023, an estimated $2.97K.
  • TCI Wealth Advisors first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 6 quarters.
  • TCI Wealth Advisors's Protagonist Therapeutics position peaked at $7K in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.